Nye sygdomsmarkører ved de kroniske myeloproliferative neoplasier

Morten Orebo Holmström; Lukas Frans Ocias; Klaus Kallenbach; Lasse Kjær; Thomas Kielsgaard Kristensen; Niels Pallisgaard; Bodil Laub Petersen; Vibe Skov; Karin de Stricker; Thomas Stauffer Larsen; Hans Carl Hasselbalch

Nye sygdomsmarkører ved de kroniske myeloproliferative neoplasier

Morten Orebo Holmström, Lukas Frans Ocias, Klaus Kallenbach, Lasse Kjær, Thomas Kielsgaard Kristensen, Niels Pallisgaard, Bodil Laub Petersen, Vibe Skov, Karin de Stricker, Thomas Stauffer Larsen, Hans Carl Hasselbalch

Publikation: Bidrag til tidsskrift › Review › peer review

Abstract

The chaperone and calcium storing protein calreticulin is coded by CALR, and newly identified mutations in CALR are found in respectively 49-70% and 56-88% of JAK2- and MPL-negative patients with essential thrombocytaemia (ET) and primary myelofibrosis (PMF). A total of 41 mutations have been identified, all located to exon 9 which codes the protein's C-terminal. CALR mutations are present only in myeloid malignancies and confer a more indolent disease than JAK2-mutated ET and PMF. CALR mutations as a diagnostic and prognostic tool are promising and the mutations are potential targets for immune therapy.

Bidragets oversatte titel	New disease markers within the chronic myeloproliferative neoplasms
Originalsprog	Dansk
Tidsskrift	Ugeskrift for Laeger
Vol/bind	177
Udgave nummer	19
ISSN	0041-5782
Status	Udgivet - 4 maj 2015
Udgivet eksternt	Ja

Citer dette

@article{2dd17b54b1a840d0b485a90d56dde30b,

title = "Nye sygdomsmark{\o}rer ved de kroniske myeloproliferative neoplasier",

abstract = "The chaperone and calcium storing protein calreticulin is coded by CALR, and newly identified mutations in CALR are found in respectively 49-70% and 56-88% of JAK2- and MPL-negative patients with essential thrombocytaemia (ET) and primary myelofibrosis (PMF). A total of 41 mutations have been identified, all located to exon 9 which codes the protein's C-terminal. CALR mutations are present only in myeloid malignancies and confer a more indolent disease than JAK2-mutated ET and PMF. CALR mutations as a diagnostic and prognostic tool are promising and the mutations are potential targets for immune therapy. ",

author = "Holmstr{\"o}m, {Morten Orebo} and Ocias, {Lukas Frans} and Klaus Kallenbach and Lasse Kj{\ae}r and Kristensen, {Thomas Kielsgaard} and Niels Pallisgaard and Petersen, {Bodil Laub} and Vibe Skov and {de Stricker}, Karin and Larsen, {Thomas Stauffer} and Hasselbalch, {Hans Carl}",

year = "2015",

month = may,

day = "4",

language = "Dansk",

volume = "177",

journal = "Ugeskrift for Laeger",

issn = "0041-5782",

publisher = "Almindelige Danske Laegeforening",

number = "19",

}

TY - JOUR

T1 - Nye sygdomsmarkører ved de kroniske myeloproliferative neoplasier

AU - Holmström, Morten Orebo

AU - Ocias, Lukas Frans

AU - Kallenbach, Klaus

AU - Kjær, Lasse

AU - Kristensen, Thomas Kielsgaard

AU - Pallisgaard, Niels

AU - Petersen, Bodil Laub

AU - Skov, Vibe

AU - de Stricker, Karin

AU - Larsen, Thomas Stauffer

AU - Hasselbalch, Hans Carl

PY - 2015/5/4

Y1 - 2015/5/4

N2 - The chaperone and calcium storing protein calreticulin is coded by CALR, and newly identified mutations in CALR are found in respectively 49-70% and 56-88% of JAK2- and MPL-negative patients with essential thrombocytaemia (ET) and primary myelofibrosis (PMF). A total of 41 mutations have been identified, all located to exon 9 which codes the protein's C-terminal. CALR mutations are present only in myeloid malignancies and confer a more indolent disease than JAK2-mutated ET and PMF. CALR mutations as a diagnostic and prognostic tool are promising and the mutations are potential targets for immune therapy.

AB - The chaperone and calcium storing protein calreticulin is coded by CALR, and newly identified mutations in CALR are found in respectively 49-70% and 56-88% of JAK2- and MPL-negative patients with essential thrombocytaemia (ET) and primary myelofibrosis (PMF). A total of 41 mutations have been identified, all located to exon 9 which codes the protein's C-terminal. CALR mutations are present only in myeloid malignancies and confer a more indolent disease than JAK2-mutated ET and PMF. CALR mutations as a diagnostic and prognostic tool are promising and the mutations are potential targets for immune therapy.

M3 - Review

C2 - 25967091

AN - SCOPUS:85018870013

VL - 177

JO - Ugeskrift for Laeger

JF - Ugeskrift for Laeger

SN - 0041-5782

IS - 19

ER -